Overview

A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults

Status:
Recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

This study will be a single-center, double-blind, randomized placebo-controlled, adaptive, single ascending dose study.

Phase:

Phase 1

Details

Lead Sponsor:

Sparian Biosciences, Inc